Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3: 1683-91. doi: 10.1001/jamaoncol.2017.3055Global Burden of Disease Liver Cancer CollaborationAkinyemijuTAberaSAhmedMAlamNAlemayohuMAetalThe burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 20152017316839110.1001/jamaoncol.2017.3055582427528983565Open DOISearch in Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatocellular carcinoma20186918223610.1016/j.jhep.2018.03.01929628281Open DOISearch in Google Scholar
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238-55. doi: 10.1093/annonc/mdy308VogelACervantesAChauIDanieleBLlovetJMMeyerTet alHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up201829iv238–5510.1093/annonc/mdy30830285213Open DOISearch in Google Scholar
Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5. doi: 10.1016/j.jhep.2012.01.008BurrelMReigMFornerABarrufetMde LopeCRTremosiniSet alSurvival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads2012561330510.1016/j.jhep.2012.01.00822314428Open DOISearch in Google Scholar
European Association for the Study of the Liver, European Organisation for Research and Treatement of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J hepatol 2012; 56: 908-43. doi: 10.1016/j.jhep.2011.12.001European Association for the Study of the Liver, European Organisation for Research and Treatement of CancerEASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma2012569084310.1016/j.jhep.2011.12.00122424438Open DOISearch in Google Scholar
Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol 2012; 81: 1173-8. doi: 10.1016/j.ejrad.2011.03.046BargelliniISaccoRBozziEBertiniMGinanniBRomanoAet alTransarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study2012811173810.1016/j.ejrad.2011.03.04621466931Open DOISearch in Google Scholar
Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81. doi: 10.1016/j.jhep.2006.10.020VarelaMRealMIBurrelMFornerASalaMBrunetMet alChemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics2007464748110.1016/j.jhep.2006.10.02017239480Open DOISearch in Google Scholar
Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61: 184-90. doi: 10.1002/hep.27443GianniniEGFarinatiFCiccareseFPecorelliARapacciniGLDiMarco Met alPrognosis of untreated hepatocellular carcinoma2015611849010.1002/hep.2744325234419Open DOISearch in Google Scholar
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016; 64: 106-16. doi: 10.1002/hep.28453LencioniRdeBaere TSoulenMCRillingWSGeschwindJFLipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data2016641061610.1002/hep.2845326765068Open DOISearch in Google Scholar
Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis 2016; 48: 571-7. doi: 10.1016/j.dld.2016.02.005FacciorussoADiMaso MMuscatielloNDrug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis201648571710.1016/j.dld.2016.02.00526965785Open DOISearch in Google Scholar
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52. doi: 10.1007/s00270-009-9711-7LammerJMalagariKVoglTPilleulFDenysAWatkinsonAet alProspective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study201033415210.1007/s00270-009-9711-7281679419908093Open DOISearch in Google Scholar
Floridi C, Radaelli A, Abi-Jaoudeh N, Grass M, Lin M, Chiaradia M, et al. C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. Radiol Med 2014; 119: 521-32. doi: 10.1007/s11547-014-0429-5FloridiCRadaelliAAbi-JaoudehNGrassMLinMChiaradiaMet alC-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications20141195213210.1007/s11547-014-0429-5420996525012472Open DOISearch in Google Scholar
Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016; 50: 418-26. doi: 10.1515/raon-2015-0045PopovicPStabucBJansaRGarbajsMSurvival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control2016504182610.1515/raon-2015-0045512057427904450Open DOISearch in Google Scholar
Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol 2012; 35: 765-74. doi: 10.1007/s00270-012-0423-zBasileACarrafielloGIerardiAMTsetisDBrountzosEQuality-improvement guidelines for hepatic transarterial chemoembolization2012357657410.1007/s00270-012-0423-z22648700Open DOISearch in Google Scholar
Lencioni R, Llovet J. Modified RECIST (mRECIST) Assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60. doi: 10.1055/s-0030-1247132LencioniRLlovetJModified RECIST (mRECIST) Assessment for hepatocellular carcinoma201030526010.1055/s-0030-124713220175033Open DOISearch in Google Scholar
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-14. doi: 10.1016/S0140-6736(11)61347-0FornerAReigMBruixJHepatocellular carcinoma201839113011410.1016/S0140-6736(11)61347-022353262Open DOISearch in Google Scholar
Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. doi: 10.1053/jhep.2003.50047LlovetJBruixJSystematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival2003374294210.1053/jhep.2003.5004712540794Open DOISearch in Google Scholar
Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010; 42(Suppl 3): S258-63. doi: 10.4254/wjh.v7.i9.1184PiscagliaFBolondiLThe intermediate hepatocellular carcinoma stage: should treatment be expanded?201042Suppl 3S2586310.4254/wjh.v7.i9.1184443849326019734Open DOISearch in Google Scholar
Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 2020; 72: 198-212. doi: 10.1002/hep.31022HanGBerhaneSToyodaHBettingerDElshaarawyOChanAWHet alPrediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach20207219821210.1002/hep.31022749633431698504Open DOISearch in Google Scholar
Xiao J, Li G, Lin S, He K, Lai H, Mo X, et al. Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization. Int J Clin Exp Pathol 2014; 7: 1114-23. PMID: 24696728XiaoJLiGLinSHeKLaiHMoXet alPrognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization20147111423PMID: 24696728Search in Google Scholar
Chen S, Peng Z, Zhang Y, Chen M, Li J, Guo R, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: Abandon or repeat? Radiology 2021; 298: 680-92. doi: 10.1148/radiol.2021202289ChenSPengZZhangYChenMLiJGuoRet alLack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: Abandon or repeat?20212986809210.1148/radiol.202120228933464183Open DOISearch in Google Scholar
Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, et al. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis 2010; 42: 515-9. doi: 10.1016/j.dld.2009.09.012OlivoMValenzaFBuccellatoAScalaLVirdoneRSciarrinoEet alTranscatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors201042515910.1016/j.dld.2009.09.01219914153Open DOISearch in Google Scholar
Suk Oh J, Jong Chun H, Gil Choi B, Giu Lee H. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. J Vasc Interv Radiol 2013; 24: 483-9. doi: 10.1016/j.jvir.2013.01.001SukOh JJongChun HGilChoi BGiuLee HTransarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response201324483910.1016/j.jvir.2013.01.00123452553Open DOISearch in Google Scholar
Ikeda M, Inaba Y, Tanaka T, Sugawara S, Kodama Y, Aramaki T, et al. A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study. [Abstract]. JCO 2020; 38(15 Suppl): 4518. doi: 10.1200/jco.2020.38.15_suppl.4518IkedaMInabaYTanakaTSugawaraSKodamaYAramakiTet alA prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study20203815 Suppl451810.1200/jco.2020.38.15_suppl.4518Open DOISearch in Google Scholar
Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol 201; 28: 207-11. doi: 10.1055/s-0031-1280666DhandSGuptaRHepatic transcatheter arterial chemoembolization complicated by postembolization syndrome201282071110.1055/s-0031-1280666319332422654264Open DOISearch in Google Scholar
Rashid M, Kwok CS, Pancholy S, Chugh S, Kedev SA, Bernat I, et al. Radial artery occlusion after transradial interventions: a systematic review and meta-analysis. J Am Heart Assoc 2016; 5: e002686. doi: 10.1161/JAHA.115.002686RashidMKwokCSPancholySChughSKedevSABernatIet alRadial artery occlusion after transradial interventions: a systematic review and meta-analysis20165e00268610.1161/JAHA.115.002686485938626811162Open DOISearch in Google Scholar
Zach V, Rapaport B, Yoo JY, Goldfeder L, Weinberger J. Multiple ischemic strokes after transcatheter arterial chemoembolization for hepatocellular carcinoma with a radiographic and pathological correlate. J Stroke Cerebrovasc Dis 2012; 21: 217-24. doi: 10.1016/j.jstrokecerebrovas-dis.2010.08.001ZachVRapaportBYooJYGoldfederLWeinbergerJMultiple ischemic strokes after transcatheter arterial chemoembolization for hepatocellular carcinoma with a radiographic and pathological correlate2012212172410.1016/j.jstrokecerebrovas-dis.2010.08.001Open DOISearch in Google Scholar
Onizuka H, Sueyoshi E, Ishimaru H, Sakamoto I, Uetani M. Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome. Abdom Radiol (NY) 2017; 42: 2544-50. doi: 10.1007/s00261-017-1168-6OnizukaHSueyoshiEIshimaruHSakamotoIUetaniMArterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome20174225445010.1007/s00261-017-1168-628493072Open DOISearch in Google Scholar